The Next Generation of Cervical Cancer Screening: Should Guidelines Focus on Best Practices for the Future or Current Screening Capacity?

Ghanaian women's perception on cervical cancer threat, severity, and the screening benefits: A qualitative study at Shai Osudoku District, Ghana

“…Cervical cancer can be detected through cervical cancer screening. It is preventable by screening for lesions at initial stages before becoming cancerous [ 1 , [13] , [14] , [15] ]. Studies have reported that more than half of their participants are aware of cervical cancer screening benefits [ [16] , [17] , [18] ].…”

Knowledge about Cervical Cancer and Awareness of Human Papillomavirus (HPV) and HPV Vaccine among Female Students from Serbia

“…Viral DNA of these high-risk strains nowadays can be easily detected in exfoliated cervical cells using commercially available tests [12]. This HPV test represents a convenient, highly sensitive screening tool that is rapidly becoming a part of screening guidelines of many countries and has a tendency of becoming the main screening method [13]. Still, it has an important flaw and that is its lower specificity [12].…”

“…Apart from this, there is also the well-known Pap smear screening method. It is widely available, cheap and has good specificity for the detection of precancerous lesions with a proven impact on reducing CC prevalence and mortality rates [13]. Organized cervical cancer screening has been conducted in Serbia since 2012 and it covers women aged 25 to 69 years [14].…”

The ASCCP Cervical Cancer Screening Task Force Endorsement and Opinion on the American Cancer Society Updated Cervical Cancer Screening Guidelines

“…Implementation of a nationwide transition to primary HPV testing presents a variety of practical concerns. As with any new screening modality, the ASCCP expects that there will be barriers to overcome to achieve full access to primary HPV testing 1 . Private and public laboratories need to adapt workflows and acquire new equipment, which requires allocating funds for both capital expenses and human resources to operationalize the new screening strategy.…”

“…As with any new screening modality, the ASCCP expects that there will be barriers to overcome to achieve full access to primary HPV testing. 1 Private and public laboratories need to adapt workflows and acquire new equipment, which requires allocating funds for both capital expenses and human resources to operationalize the new screening strategy. In addition, health care systems, private offices, and community-based health centers must coordinate with laboratories and payers to implement HPV primary screening with correct new codes for using cytology as a reflex test and billing with potential payment restrictions in some settings.…”